CN104812756A - 多激酶通路抑制剂 - Google Patents
多激酶通路抑制剂 Download PDFInfo
- Publication number
- CN104812756A CN104812756A CN201380060317.8A CN201380060317A CN104812756A CN 104812756 A CN104812756 A CN 104812756A CN 201380060317 A CN201380060317 A CN 201380060317A CN 104812756 A CN104812756 A CN 104812756A
- Authority
- CN
- China
- Prior art keywords
- dialkylamino
- compound
- alkyl
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCN(CC)CCOc(cc1)cnc1NC1=NC(C)C(C=C(C(C)C)C(N2C)=*)C2=C1 Chemical compound CCN(CC)CCOc(cc1)cnc1NC1=NC(C)C(C=C(C(C)C)C(N2C)=*)C2=C1 0.000 description 3
- VRZCYKSQWBFIID-UHFFFAOYSA-N BC(CC(C)=C1)=CN=C1[N+]([O-])=O Chemical compound BC(CC(C)=C1)=CN=C1[N+]([O-])=O VRZCYKSQWBFIID-UHFFFAOYSA-N 0.000 description 1
- KHZRSRXBKDNVBS-UHFFFAOYSA-N CCN(c1cc(Nc(cc2)ncc2F)ncc1C=C1c(c(F)ccc2)c2F)C1=O Chemical compound CCN(c1cc(Nc(cc2)ncc2F)ncc1C=C1c(c(F)ccc2)c2F)C1=O KHZRSRXBKDNVBS-UHFFFAOYSA-N 0.000 description 1
- CXTTVIBTVIQTTE-UHFFFAOYSA-N CCN(c1cc(Nc(cc2)ncc2F)ncc1C=C1c2ccccc2F)C1=O Chemical compound CCN(c1cc(Nc(cc2)ncc2F)ncc1C=C1c2ccccc2F)C1=O CXTTVIBTVIQTTE-UHFFFAOYSA-N 0.000 description 1
- USAIOQRAKMNIBJ-UHFFFAOYSA-N CCN(c1cc(Nc(cc2)ncc2NCCO)ncc1C=C1c2ccccc2)C1=O Chemical compound CCN(c1cc(Nc(cc2)ncc2NCCO)ncc1C=C1c2ccccc2)C1=O USAIOQRAKMNIBJ-UHFFFAOYSA-N 0.000 description 1
- HUZUQWILDNGCFH-UHFFFAOYSA-N CCN(c1cc(Nc2ncc(CCN(C)C)[s]2)ncc1C=C1c2ccccc2)C1=O Chemical compound CCN(c1cc(Nc2ncc(CCN(C)C)[s]2)ncc1C=C1c2ccccc2)C1=O HUZUQWILDNGCFH-UHFFFAOYSA-N 0.000 description 1
- MFTSMDMNXWZCJQ-UHFFFAOYSA-N CCN1C2=CC(Nc3ccc(C)cn3)=NCC=C2C=C(CC(C)C)C1O Chemical compound CCN1C2=CC(Nc3ccc(C)cn3)=NCC=C2C=C(CC(C)C)C1O MFTSMDMNXWZCJQ-UHFFFAOYSA-N 0.000 description 1
- NCWNVZMHTRKEOP-INIZCTEOSA-N CN(CC1)C[C@H]1N(c1cc(Nc(cc2)ncc2F)ncc1C=C1c(c(F)ccc2)c2F)C1=O Chemical compound CN(CC1)C[C@H]1N(c1cc(Nc(cc2)ncc2F)ncc1C=C1c(c(F)ccc2)c2F)C1=O NCWNVZMHTRKEOP-INIZCTEOSA-N 0.000 description 1
- XRYGCVVVDCEPRL-UHFFFAOYSA-N CNC1CCN(C)CC1 Chemical compound CNC1CCN(C)CC1 XRYGCVVVDCEPRL-UHFFFAOYSA-N 0.000 description 1
- MQSHODMZMFZJNV-HNNXBMFYSA-N O=C(C(c(c(F)ccc1)c1F)=C1)N([C@@H]2CNCC2)c2c1cnc(Nc(cc1)ncc1F)c2 Chemical compound O=C(C(c(c(F)ccc1)c1F)=C1)N([C@@H]2CNCC2)c2c1cnc(Nc(cc1)ncc1F)c2 MQSHODMZMFZJNV-HNNXBMFYSA-N 0.000 description 1
- VRPKTAYROQZASH-UHFFFAOYSA-N O=C1N(C2CCCC2)c2cc(Nc(nc3)ccc3F)ncc2C=C1c(c(F)ccc1)c1F Chemical compound O=C1N(C2CCCC2)c2cc(Nc(nc3)ccc3F)ncc2C=C1c(c(F)ccc1)c1F VRPKTAYROQZASH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706084P | 2012-09-26 | 2012-09-26 | |
| US61/706,084 | 2012-09-26 | ||
| US201361757331P | 2013-01-28 | 2013-01-28 | |
| US61/757,331 | 2013-01-28 | ||
| US201361785992P | 2013-03-14 | 2013-03-14 | |
| US61/785,992 | 2013-03-14 | ||
| PCT/US2013/061548 WO2014052365A1 (en) | 2012-09-26 | 2013-09-25 | Multiple kinase pathway inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104812756A true CN104812756A (zh) | 2015-07-29 |
Family
ID=50388917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380060317.8A Pending CN104812756A (zh) | 2012-09-26 | 2013-09-25 | 多激酶通路抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9493454B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2900668A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015532281A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104812756A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013323736A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2886275A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1212683A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014052365A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105130986A (zh) * | 2015-09-30 | 2015-12-09 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| WO2018108167A1 (zh) * | 2016-12-16 | 2018-06-21 | 基石药业 | Cdk4/6抑制剂 |
| CN108264511A (zh) * | 2017-01-03 | 2018-07-10 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和其在医药上的用途 |
| WO2024012543A1 (zh) * | 2022-07-14 | 2024-01-18 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| AU2013323736A1 (en) * | 2012-09-26 | 2015-04-09 | Mannkind Corporation | Multiple kinase pathway inhibitors |
| MX394360B (es) | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| CN104418853B (zh) * | 2013-08-28 | 2016-09-07 | 北大方正集团有限公司 | 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物 |
| CN105622638B (zh) * | 2014-10-29 | 2018-10-02 | 广州必贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
| WO2016161248A1 (en) * | 2015-04-02 | 2016-10-06 | Tolero Pharmaceuticals, Inc. | Targeting pim kinases in combination with btk inhibition |
| KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| JP7083497B2 (ja) | 2015-08-03 | 2022-06-13 | スミトモ ファーマ オンコロジー， インコーポレイテッド | がんの処置のための併用療法 |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| KR20210003780A (ko) | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | Axl 키나제 억제제 및 그의 용도 |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| CA3120850A1 (en) * | 2018-12-07 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating castration-resistant and castration- sensitive prostate cancer |
| KR20260008165A (ko) | 2019-02-12 | 2026-01-15 | 스미토모 파마 아메리카, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| CN120302975A (zh) | 2022-10-31 | 2025-07-11 | 住友制药美国公司 | 治疗骨髓增生性肿瘤的pim1抑制剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150359A (en) * | 1997-08-20 | 2000-11-21 | Warner-Lambert Company | Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| US20030144351A1 (en) * | 1998-08-21 | 2003-07-31 | Parker Hughes Institute | BTK inhibitors and methods for their identification and use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| MXPA05007503A (es) * | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MX2008014618A (es) * | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
| WO2007136790A2 (en) | 2006-05-18 | 2007-11-29 | Mannkind Corporation | Intracellular kinase inhibitors |
| AU2013323736A1 (en) * | 2012-09-26 | 2015-04-09 | Mannkind Corporation | Multiple kinase pathway inhibitors |
-
2013
- 2013-09-25 AU AU2013323736A patent/AU2013323736A1/en not_active Abandoned
- 2013-09-25 US US14/431,476 patent/US9493454B2/en not_active Expired - Fee Related
- 2013-09-25 HK HK16100505.0A patent/HK1212683A1/zh unknown
- 2013-09-25 EP EP13840649.1A patent/EP2900668A4/en not_active Withdrawn
- 2013-09-25 CN CN201380060317.8A patent/CN104812756A/zh active Pending
- 2013-09-25 CA CA 2886275 patent/CA2886275A1/en active Pending
- 2013-09-25 WO PCT/US2013/061548 patent/WO2014052365A1/en not_active Ceased
- 2013-09-25 JP JP2015534612A patent/JP2015532281A/ja active Pending
-
2016
- 2016-09-26 US US15/276,604 patent/US9714247B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150359A (en) * | 1997-08-20 | 2000-11-21 | Warner-Lambert Company | Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| US20030144351A1 (en) * | 1998-08-21 | 2003-07-31 | Parker Hughes Institute | BTK inhibitors and methods for their identification and use |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018534352A (ja) * | 2015-09-30 | 2018-11-22 | グアンジョウ ベベター メディシン テクノロジー カンパニー リミテッド | ピリミジン又はピリドピロドン類化合物、及びその応用 |
| WO2017054484A1 (zh) * | 2015-09-30 | 2017-04-06 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| CN105130986A (zh) * | 2015-09-30 | 2015-12-09 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| US10183941B2 (en) * | 2015-09-30 | 2019-01-22 | Guangzhou Bebetter Medicine Technology Co., Ltd. | Pyrimidine or pyridopyridone compound and application thereof |
| AU2016333188B2 (en) * | 2015-09-30 | 2018-10-25 | Bebetter Med Inc. | Pyrimidine or pyridopyridone compound and application thereof |
| US10676474B2 (en) | 2016-12-16 | 2020-06-09 | Cstone Pharmaceuticals | 1,6-naphthyridine derivatives as CDK4/6 inhibitor |
| KR20190092549A (ko) * | 2016-12-16 | 2019-08-07 | 씨스톤 파마슈티컬즈 | Cdk4/6 억제제 |
| CN110382495A (zh) * | 2016-12-16 | 2019-10-25 | 基石药业 | Cdk4/6抑制剂 |
| WO2018108167A1 (zh) * | 2016-12-16 | 2018-06-21 | 基石药业 | Cdk4/6抑制剂 |
| TWI749126B (zh) * | 2016-12-16 | 2021-12-11 | 大陸商基石藥業（蘇州）有限公司 | Cdk4/6抑制劑 |
| CN110382495B (zh) * | 2016-12-16 | 2022-04-05 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂 |
| KR102513448B1 (ko) | 2016-12-16 | 2023-03-23 | 씨스톤 파마슈티컬즈 | Cdk4/6 억제제 |
| CN108264511A (zh) * | 2017-01-03 | 2018-07-10 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和其在医药上的用途 |
| CN108264511B (zh) * | 2017-01-03 | 2021-04-13 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和其在医药上的用途 |
| WO2024012543A1 (zh) * | 2022-07-14 | 2024-01-18 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170107215A1 (en) | 2017-04-20 |
| CA2886275A1 (en) | 2014-04-03 |
| JP2015532281A (ja) | 2015-11-09 |
| AU2013323736A8 (en) | 2015-04-30 |
| US9493454B2 (en) | 2016-11-15 |
| WO2014052365A1 (en) | 2014-04-03 |
| EP2900668A4 (en) | 2016-04-20 |
| US9714247B2 (en) | 2017-07-25 |
| AU2013323736A1 (en) | 2015-04-09 |
| EP2900668A1 (en) | 2015-08-05 |
| HK1212683A1 (zh) | 2016-06-17 |
| US20150266870A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104812756A (zh) | 多激酶通路抑制剂 | |
| JP6475158B2 (ja) | Ｍｎｋ１およびｍｎｋ２調節剤としての二環式ヘテロアリール誘導体、およびその使用 | |
| JP7373992B2 (ja) | 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法 | |
| CN102203093B (zh) | 氨基三唑并吡啶和其作为激酶抑制剂的用途 | |
| CN101952287B (zh) | 蛋白激酶抑制剂及其应用 | |
| RU2569635C9 (ru) | ЗАМЕЩЕННЫЕ ПИРИДОПИРАЗИНЫ КАК НОВЫЕ ИНГИБИТОРЫ Syk | |
| WO2018153373A1 (zh) | Fgfr抑制剂及其应用 | |
| CN112601752A (zh) | Map4k1的新颖抑制剂 | |
| JP2022521901A (ja) | タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物 | |
| CA3106961A1 (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| RS61919B1 (sr) | Inhibitori hpk1 i postupci za njihovo korišćenje | |
| CN102361859A (zh) | 用作Raf激酶抑制剂的杂芳基化合物 | |
| KR101921764B1 (ko) | 피라졸로-퀴놀린 | |
| CN102137866A (zh) | 羟吲哚化合物 | |
| WO2015050505A1 (en) | Bicyclic alkyne derivatives and uses thereof | |
| JP2022518723A (ja) | ピロロピリジン誘導体およびタンパク質キナーゼ関連疾患の予防または治療での使用のためのその用途 | |
| EP4358954A1 (en) | Cdk2 inhibitors and methods of using the same | |
| CN117730083A (zh) | 用作map4k1抑制剂的嘧啶化合物 | |
| RU2807277C2 (ru) | Соединения пиримидина и содержащие их фармацевтические композиции для предупреждения или лечения рака | |
| TWI759829B (zh) | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 | |
| JP2025536323A (ja) | 縮合二環式化合物ならびにＭｅｒ阻害剤およびＡｘｌ阻害剤としてのその使用 | |
| HK40009843A (en) | Fgfr inhibitor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150729 |